With 0.75 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.2 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.37 whereas the lowest price it dropped to was $3.03. The 52-week range on PRME shows that it touched its highest point at $9.77 and its lowest point at $2.56 during that stretch. It currently has a 1-year price target of $13.09. Beta for the stock currently stands at 1.81.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PRME was up-trending over the past week, with a rise of 13.95%, but this was up by 7.03% over a month. Three-month performance dropped to -1.76% while six-month performance fell -36.07%. The stock lost -62.23% in the past year, while it has gained 14.73% so far this year. A look at the trailing 12-month EPS for PRME yields -2.01 with Next year EPS estimates of -1.34. For the next quarter, that number is -0.40. This implies an EPS growth rate of 21.99% for this year and 21.03% for next year.
Float and Shares Shorts:
At present, 131.16 million PRME shares are outstanding with a float of 50.89 million shares on hand for trading. On 2024-12-13, short shares totaled 16.13 million, which was 1230.0 higher than short shares on 1731628800. In addition to Dr. Keith Michael Gottesdiener M.D., Ph.D. as the firm’s President, CEO, Secretary & Director, Dr. Ann L. Lee Ph.D. serves as its Chief Technical Officer.
Institutional Ownership:
Through their ownership of 0.62348 of PRME’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PRME reported revenue of $209000.0 and operating income of -$54232000.0. The EBITDA in the recently reported quarter was -$52889000.0 and diluted EPS was -$0.44.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PRME since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PRME analysts setting a high price target of 19.0 and a low target of 7.0, the average target price over the next 12 months is 13.09091. Based on these targets, PRME could surge 467.16% to reach the target high and rise by 108.96% to reach the target low. Reaching the average price target will result in a growth of 290.77% from current levels.
Analysts have provided yearly estimates in a range of -$1.39044 being high and -$1.91061 being low. For PRME, this leads to a yearly average estimate of -$1.70054.
